MNKD: 2026 FDA Decisions On Inhaled Insulin Will Reframe Royalty Risk

Analysts have trimmed their fair value view on MannKind to $7.50 from $9.61, citing lower price targets clustered around $3.50 to $11 as they factor in softer revenue growth and profit margin assumptions, as well as higher perceived risk tied to United Therapeutics' potential soft mist inhaler competition and the timing of Tyvaso DPI royalty data.

Analyst Commentary

Recent Street research on MannKind reflects a wide split in opinion, with some analysts focusing on potential upside from the broader product portfolio and others emphasizing new competitive risks to Tyvaso DPI royalties and collaboration revenue.

Bullish Takeaways

• Bullish analysts highlight that the recent Q4 update showed solid revenue across all commercial assets. They view this as support for MannKind's ability to fund increased investments planned for 2026.
• Several bullish views point to Furoscix and Afrezza as key drivers that could help the stock outperform over time, particularly if execution around product uptake and label expansion aligns with the company's plans.
• Some bulls see the recent selloff, with shares described as down around 30% to 40% after the soft mist inhaler news, as a possible reset of MannKind's value proposition that may already reflect a worst case scenario on Tyvaso DPI before details are clear.
• Supportive research notes argue that very little value is currently ascribed to possible 2026 catalysts, including regulatory decisions on Afrezza dose conversion and pediatric use. They consider these underappreciated sources of potential growth.

Bearish Takeaways

• Bearish analysts have cut price targets into the US$3.50 to US$8 range and contend that the outlook for Tyvaso DPI royalties may remain an overhang, as more definitive royalty data is not expected until 2027.
• The development of United Therapeutics' soft mist inhaler for treprostinil, if approved, is viewed as a material risk that could potentially displace some Tyvaso DPI use. In turn, this could weigh on MannKind's future royalty and collaboration revenue assumptions.
• Some cautious views stress that proving the more optimistic case for Tyvaso credit in the share price, described as US$2 to US$3 per share, may be difficult in the near term given limited visibility into how the soft mist inhaler and DPI formulations will coexist.
• Concerns also center on execution risk around 2026 investment plans, with skeptics questioning whether higher spending will translate into the level of revenue durability and growth needed to support prior, higher fair value estimates.

What's in the News

• First patient enrolled in INHALE-1ST, a clinical study evaluating Afrezza Inhalation Powder initiated shortly after a type 1 diabetes diagnosis in pediatric patients, in combination with once daily basal insulin in youth aged 10 and older (company announcement).
• FDA accepted for review a supplemental Biologics License Application for Afrezza in children and adolescents with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026. If approved, this could make Afrezza the first needle free insulin option for pediatric patients in more than 100 years of insulin therapy (company announcement).
• FDA approved an update to Afrezza Prescribing Information, revising recommendations for starting mealtime dosage when switching from subcutaneous mealtime insulin. The update is supported by modeling data and in vivo results from the Dose Optimization study and INHALE-3 trial (company announcement).
• Labeling for Afrezza now includes detailed dose conversion recommendations from injected mealtime insulin or insulin pump bolus dosing to Afrezza mealtime doses, with continued emphasis on spirometry monitoring, pulmonary function, and DKA risk in type 1 diabetes (company announcement).
• FUROSCIX On-body Infusor received FDA approval for use in pediatric patients weighing 43 kg or more. The USPTO also issued five patents covering the FUROSCIX ReadyFlow Autoinjector and related high concentration furosemide formulations, with potential protection through 2040 if the product is approved and listed in the FDA Orange Book (company announcement).

Valuation Changes

• Fair Value: trimmed from $9.61 to $7.50, a reduction of roughly 22% that reflects more conservative assumptions across the model.
• Discount Rate: increased from 7.28% to 8.08%, indicating a higher implied risk profile and a larger required return from the shares.
• Revenue Growth: reduced from 21.58% to 16.44%, suggesting a more cautious stance on how quickly $ revenue could expand over the forecast period.
• Net Profit Margin: lowered from 20.25% to 13.96%, pointing to a tighter view on future profitability and cost leverage.
• Future P/E: raised from 32.95x to 39.38x, which implies a higher multiple being applied to the updated earnings outlook despite more conservative growth and margin inputs.